The company is tapping artificial intelligence and advanced analytics to build a “cognitive CDMO” connecting scientific knowledge with operational data.
The Frankfurt campus will add active pharmaceutical ingredient capacity, with production planned for 2032, as the company expands its global biologics and vaccine network.
The potential financing would support U.S. manufacturing of critical pharmaceutical ingredients, building on existing federal-backed efforts to expand biosynthesis production.
